Identification of Volatile Biomarkers of Gastric Cancer Cells and Ultrasensitive Electrochemical Detection based on Sensing Interface of Au-Ag Alloy coated MWCNTs

Abstract

Successful development of novel electrochemical biosensing interface for ultrasensitive detection of volatile biomarkers of gastric cancer cells is a challenging task. Herein we reported to screen out novel volatile biomarkers associated with gastric cancer cells and develop a novel Au-Ag alloy composites-coated MWCNTs as sensing interface for ultrasensitive detection of volatile biomarkers. MGC-803 gastric cancer cells and GES-1 gastric mucous cells were cultured in serum-free media. The sample preparation approaches and HS-SPME conditions were optimized for screening volatile biomarkers. Volatiles emitted from the headspace of the cells/medium culture were identified using GC-MS. The Au-Ag nanoparticles-coated multiwalled carbon nanotubes were prepared as a sensing interface for detection of volatile biomarkers. Results showed that eight different volatile metabolites were screened out between MGC-803 cells and GES-1 cells. Two compounds such as 3-octanone and butanone were specifically present in the headspace of the MGC-803 cells. Three volatiles such as 4-isopropoxybutanol, nonanol and 4-butoxy 1-butanol coexisted in the headspace of both the MGC-803 cells and the GES-1 cells, their concentrations in the headspace of the GES-1cells were markedly higher than those in the MGC-803 cells, three volatiles such as formic acid propyl ester, 1.4-butanediol and 2, 6, 11-trimethyl dodecane solely existed in the headspace of the GES-1 cells. The nanocomposites of MWNTs loaded with Au-Ag nanoparticles were prepared as a electrochemical sensing interface for detection of two volatile biomarkers, cyclic voltammetry studies showed that the fabricated sensor could detect 3-octanone in the range of 0~0.0025% (v/v) and with a detection limitation of 0.3 ppb, could detect butanone in the range of 0 ~ 0.055% (v/v), and with a detection limitation of 0.5 ppb, and exhibited good selectivity. The novel electrochemical biosensor combined with volatile biomarkers of gastric cancer owns great potential in applications such as early diagnosis and the prognosis of gastric cancer in near future.

Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules

“…35 Nanotechnology-based chemical sensor matrices based on nanomaterials could serve as the translational tool leading from fundamental research to the modern point-of-care practice. 6,7,22,36−38 This is because chemical sensor matrices are significantly smaller, easier to use, and less expensive than other sensing devices. Basically, recognition of VOCs by nanotechnology-based sensors can be achieved by selective detection of (pre)identified VOCs.…”

EGFR Antibody Conjugated Bimetallic Au@Ag Nanorods for Enhanced SERS-Based Tumor Boundary Identification, Targeted Photoacoustic Imaging and Photothermal Therapy

“…In our previous work, with the aim of finding early gastric cancer, we screen out some new biomarkers associated with early gastric cancer and develop novel ultrasensitive detection methods [8][9]. We also designed and fabricated some multifunctional nanoprobes for targeted imaging and simultaneous therapy of subcutaneous and in situ gastric cancer tissues with 5 mm in diameter [10][11][12][13][14][15][16][17][18][19][20][21][22]. Among those multifunctional nanoprobes, RGDconjugated gold nanorods could target tumor tissues and kill tumor cells via photothermal therapy [14], exhibiting potential clinical application prospects.…”

SPME as a promising tool in translational medicine and drug discovery: From bench to bedside

“…Based on the profiles obtained, the authors were able to indicate the serum-substituted and serum-free complete mediums as not appropriate for cell growth due to a negative effect on metabolism [62]. Among other examples, HS-SPME was also used for assessment of biomarkers suitable for early screening of gastric cancer [63]. In this study, two cancer cell lines (MGC-803 gastric cancer cells and GES-1 gastric mucous cells) were employed.…”